Oric Pharmaceuticals shares are trading lower after the company announced an update from the Phase 1b trial of rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.

Benzinga Newsdesk www.benzinga.com Negative 96.3%

Neg 96.3% Neu 0% Pos 0%

Comments

No comments yet. Be the first!